AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A composition for use in treating epithelial lesions formed of a combination of ingredients comprising:

8-hydroxyquinoline in an amount of at least five percent of the composition by weight;

~~an escharotic chelatable metal agent~~ zinc bonded to said 8-hydroxyquinoline, the ~~escharotic chelatable metal agent comprising a metal having an oxidation state of +2~~ zinc being present in a concentration of at least five percent by weight of the composition and less than an amount that produces an eschar in healthy mammalian tissues; and

a carrier,

the composition being a pharmaceutical grade material having a capacity for treating at least one type of lesion selected from the group consisting of venereal warts, male veruoca warts, lesions produced by the human papilloma virus, basal cell carcinoma, solar keratosis, Kaposi's sarcoma, eye cancer, sarcoids, sarcoma, malignant melanoma, rectal adenoma, histocytoma, sebaceous adenoma, lung cancer, breast cancer, and colon cancer.

2. (Currently amended) The composition as set forth in claim 1, wherein the ~~escharotic chelatable metal agent includes~~ zinc is present in a molar ratio (8-hydroxyquinoline:zinc) ranging from 1:1 to 1:3.

3. (Previously presented) The composition as set forth in claim 2 wherein said molar ratio is about 1:2.

4. (Cancelled)

5. (Currently amended) The composition as set forth in claim 1 wherein ~~said escharotic chelatable metal agent comprises~~ the zinc is provided in the composition as zinc chloride in an amount ranging up to forty percent by weight of said composition by weight.

6. (Currently amended) The composition as set forth in claim 1 wherein ~~said escharotic chelatable metal agent comprises~~ the zinc is provided in the composition as zinc chloride in an amount ranging up to twenty percent of said composition by weight.

7. (Previously presented) The composition as set forth in claim 1 in combination with necrotic tissue from a lesion of said group produced by the action of said composition upon the lesion.

8-13. (Cancelled.)

14. (Previously presented) The composition as set forth in claim 1, wherein said carrier comprises a gel.

15. (Previously presented) The composition as set forth in claim 14 wherein said gel comprises a polyoxyalkylene ether derivative of propylene glycol.

16. (Previously presented) The composition as set forth in claim 1 wherein said carrier contains a penetrant selected from the group consisting of lecithin and dimethyl sulfoxide.

17. (Previously presented) The composition as set forth in claim 16 wherein said penetrant is lecithin.

18. (Previously presented) The composition as set forth in claim 16 wherein said penetrant is dimethyl sulfoxide.

19. (Previously presented) The composition as set forth in claim 1 wherein said carrier contains an antioxidant selected from the group consisting of nordihydroguiaretic acid and ascorbic acid.

20. (Currently amended) The composition as set forth in claim 19 wherein said antioxidant includes at least nordihydroguiaretic acid.

21. (Currently amended) The composition as set forth in claim 19 wherein said antioxidant includes at least ascorbic acid.

22-33 (Cancelled)

34. (Previously presented) The composition as set forth in claim 1 wherein said carrier consists essentially of an antioxidant selected from the group consisting of nordihydroguiaretic acid and ascorbic acid.

35. (Currently amended) The composition as set forth in claim 34 wherein said antioxidant consists essentially of ~~an~~ ascorbic acid ~~a~~.

36. (Original) The composition as set forth in claim 34 wherein the antioxidant consists essentially of nordihydroguiaretic acid.

37-38 (Cancelled)

39-50. (Cancelled)

51-52 (Cancelled)